

RFP/PPRVB/2021 Questions and Answers (15/03/21)

This document is established to centralise the responses to all the questions the OIE receives related to the OIE PPR Vaccine Bank call for tender (reference RFP/PPRVB/2021).

| RFP Section | Question | Answer |
|-------------------------------|---|---|
| General | Could we have the documents in French (Documents A and B)? | The documents unfortunately only exist in English. While the official languages of the OIE are English, French and Spanish, documents related to a call for tender are not part of the official publication which have to comply with the translations in the three languages, this for reasons of efficiency. As mentioned in article 4.5 of the Tender's procedure rules " <i>Tenders, namely the envelope including the technical offer and the envelope including the financial offer, must be submitted in English</i> " and a publication in English was therefore the most appropriate for this call for tender. |
| General | Technical offer. Is there any specific format we have to use? Please send us accordingly to proceed further. | There is no preestablished template for the technical offer. However, there is a structure outlined in article 4.1 "TECHNICAL RESPONSE" of the Terms of reference, in particular: <ul style="list-style-type: none"> - General company information - Nature and quality of the vaccines - Service proposed (services offered) - Success – risk factors - Additional information |
| General | Financial offer. Is there any specific format we have to use? Please send us accordingly to proceed further. | There is no preestablished template for the financial offer, however, tenderers should make sure they respond to all the requested elements mentioned in article 4.2 of the Terms of reference "FINANCIAL OFFER". |
| Tender Procedure Rules | | |
| ANNEX 3 DRAFT CONTRACT | <p>ANNEX 1 of the draft contract "Templates for Production & Delivery Order and Delivery Order" Do we have to fill this detail now or after award of tender?</p> <p>Annex 2 of the draft contract "Contacts" Who will provide us OIE personnel details?</p> <p>Annex 3 of the draft contract "Contact information and financial details to be provided to [Company name]" Do we have to provide details now or after award of Tender?</p> <p>Annex 4 of the draft contract "List of countries for vaccine delivery and shipping constraints" Do we have to mention all countries in Africa only or Asia and others?</p> | <p>As mentioned in article 4.3 "TENDER DOCUMENTS" of the Tender's Procedure Rules, the Annex 3 "Draft Contract" (including its 6 specific annexes) is for information only and therefore the tenderer is not requested to fill it in. It is only required that the tenderer signs it, as further indicated in article 4.5 "RESPONSE FORMAT REQUIREMENTS", in order to acknowledge that the documents have been read and understood by the tenderer.</p> <p>The tenderer needs to read the content of this draft contract to make sure it understands and is comfortable with the contract that will be signed between the awarded tenderers and the OIE at the end of the process.</p> <p>If the tenderer considers that some elements of the draft contract are difficult to comply with, the tenderer should precise which ones and what their counter proposal is in their offer.</p> <p>Regarding the list of countries, likewise to the other elements of the draft contract, tenderers are not required to fill this table in. The tenderer can however decide to use this template to respond to the Terms of reference request for a "list of countries where the manufacturer is able to deliver". To clarify its geographical scope, the OIE PPR Vaccine Bank is global and does not focus on a specific region. It is however expected that requests and deliveries will be predominantly in the region of Africa, in particular West Africa. Tenderers should therefore indicate their capacity to deliver in all countries that could need PPR vaccines, even beyond Africa.</p> |

| Terms of Reference | | |
|-----------------------------------|---|--|
| § 3.2 The PPR Vaccine Bank | Please clarify the 'Early Release Certificate'? | <p>The Early Release Certificate should be understood as follows: in the event that the ordering entity justifies an emergency to receive a delivery of vaccines, the company agrees to propose to the ordering entity a shipment of vaccines for which part of the quality control is still in progress, informing the ordering entity of the nature of the controls that remain to be finalised and the time limit within which all the verifications will have been carried out.</p> <p>The Certificate disclaims the manufacturer of all responsibility in the event of the use of vaccines for which the subsequent verifications would raise concerns.</p> |
| § 3.4 PPR Vaccines | Please clarify the 'remaining shelf-life'. | <p>Vaccines are expected to have 2 years shelf-life at manufacture, and suppliers are expected to manage inventory and offer vaccine stocks in response to requests in a manner that ensures sufficient remaining shelf-life when used in accordance with the recipient countries intentions as indicated in the request documentation. A description of this inventory management system to guarantee shelf-life of deliveries is expected.</p> |